内幕信息知情人管理
Search documents
赛隆药业集团股份有限公司 关于董事、高级管理人员 2025年薪酬的确认及2026年薪酬方案
Zheng Quan Ri Bao· 2026-02-03 23:21
Core Viewpoint - The company has proposed a compensation plan for its directors and senior management for 2026, which aims to enhance their motivation and creativity while aligning their performance with the company's operational effectiveness [1][2]. Group 1: 2025 Compensation Confirmation - The compensation details for the company's directors and senior management for 2025 were reviewed and confirmed, with specific individuals noted as non-independent directors who do not receive compensation [1]. Group 2: 2026 Compensation Plan - The 2026 compensation plan applies to both directors (including independent directors) and senior management [2]. - The plan will take effect upon approval by the shareholders' meeting and will automatically become invalid once a new plan is approved [3]. - Independent directors will receive an annual allowance of 180,000 yuan, paid monthly [4]. - Non-independent directors, including the chairman and vice-chairman, will have a salary structure consisting of a base salary and performance-based compensation, with performance pay accounting for at least 50% of the total compensation [5]. - Senior management's compensation will also consist of a base salary and performance pay, with similar performance-based criteria [6]. Group 3: Additional Provisions - Compensation for directors and senior management who leave due to changes in position or resignation will be calculated based on their actual tenure [7]. - All compensation figures are pre-tax, with the company responsible for withholding taxes and social insurance as per regulations [7]. - The company reserves the right to reduce or stop performance pay if directors or senior management violate obligations that result in losses to the company [7]. - The human resources and finance departments are authorized to implement the compensation plan, while the compensation and assessment committee will oversee its execution [7].
盛路通信: 内幕信息知情人登记管理制度(2025年7月)
Zheng Quan Zhi Xing· 2025-07-08 10:18
广东盛路通信科技股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为进一步规范广东盛路通信科技股份有限公司(以下简称"公司") 内幕信息知情人管理,加强内幕信息保密工作,维护公司信息披露的公开、公平、 公正原则,根据《中华人民共和国公司法》(以下简称《公司法》)、《中华人 民共和国证券法》(以下简称《证券法》)、《上市公司监管指引第 5 号—上市 公司内幕信息知情人登记管理制度》、《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等法律、 法规、规范性文件和《广东盛路通信科技股份有限公司章程》(以下简称"公司 章程")的有关规定,制定本制度。 第二章 内幕信息知情人及其范围 第五条 内幕信息知情人是指可以接触、获取公司内幕信息的公司内部和 外部相关人员。 第六条 内幕信息知情人包括但不限于: (一)公司的董事、高级管理人员; (二)持有公司百分之五以上股份的股东及其董事、监事、高级管理人员, 公司的实际控制人、第一大股东、实际控制人及其董事、监事、高级管理人员; 第三条 公司董事长为内幕信息管理工作的主要责任人,董事会秘书负责 办理公司内幕信 ...
复星医药: 复星医药内幕信息知情人管理制度(2025年修订)
Zheng Quan Zhi Xing· 2025-06-24 19:03
Core Viewpoint - The document outlines the insider information management system of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., aiming to regulate the management of insider information and protect investors' rights in accordance with relevant laws and regulations. Group 1: General Principles - The company establishes this system to ensure the public, fair, and just disclosure of insider information and to protect investors' legal rights [1] - The board of directors is responsible for maintaining accurate and complete insider information records, with the chairman as the primary responsible person [1] Group 2: Definition and Scope of Insider Information - Insider information refers to undisclosed information that could significantly impact the company's operations, finances, or market price of its securities [2] - Examples of insider information include major events affecting stock prices, significant changes in assets, liabilities, or operational results, and legal actions against key personnel [2][3] Group 3: Insider Information Recipients - Insider information recipients include company directors, senior management, shareholders holding over 5% of shares, and other individuals or entities that can access insider information due to their roles [4] Group 4: Registration and Reporting of Insider Information Recipients - The company must record and report the list of insider information recipients promptly before the information is publicly disclosed [5] - Various stakeholders, including shareholders and service providers, are required to cooperate in maintaining accurate records of insider information recipients [5][6] Group 5: Reporting Obligations - The company must report insider information recipient records to the Shanghai Stock Exchange for significant events such as major asset restructuring and changes in control [7][8] - The reporting must include a comprehensive list of involved parties, including directors, major shareholders, and relevant service providers [8] Group 6: Confidentiality and Accountability - Insider information recipients have a duty to maintain confidentiality and are prohibited from trading the company's securities before public disclosure [10][11] - Violations, such as leaking insider information or engaging in insider trading, will result in penalties and potential criminal prosecution [11][19] Group 7: Miscellaneous Provisions - The system will be effective upon approval by the board of directors and will be revised as necessary [13]